Vidari: Benefits, Evidence, Dosage & Safety
TL;DR
Vidari (Pueraria tuberosa) is the same plant as our Vidarikand article, which covers a randomized trial for blood pressure. This article covers the classical Vidari entry: a sweet, cooling Ayurvedic rejuvenative traditionally used for strength, reproductive health, and lactation support. Beyond that trial, published human data to date is one small lactation study; the rest is animal and laboratory evidence.
What it is
Vidari is the classical Sanskrit name for the tuber of Pueraria tuberosa (Roxb. ex Willd.) DC., a perennial woody climber of the legume family (Fabaceae) with very large tuberous roots, distributed across India and commonly called Indian kudzu (Bharti et al., Frontiers in Pharmacology). The tuber is the medicinal part, and its studied constituents include the isoflavonoid puerarin and related compounds (same review). Its Ayurvedic synonyms include Bhumikusmanda, Svadukanda, and Ikshugandha (the Ayurvedic Pharmacopoeia of India lists "Vidari" among its synonyms) (same review).
A note on our two articles: this plant appears on this site under two names. Our Vidarikand article covers the single human randomized trial (3 g/day of tuber powder for blood pressure) and the safety discussion. This Vidari article covers the classical Ayurvedic entry: the properties, traditional uses, and formulations described in the Samhitas and nighantus. The two are companions, not duplicates.
Traditional use
Vidari is described in all the major Ayurvedic classics and nighantus. Its Ayurvedic properties are given as madhura rasa (sweet taste), shita virya (cooling potency), madhura vipaka (sweet post-digestive effect), and guru, snigdha guna (heavy, unctuous qualities), pacifying Vata, Pitta, and Rakta (IJAAR classical review). It is credited with balya (strength-promoting), jivaniya (life-promoting), vrishya (aphrodisiac), rasayana (rejuvenative), shukrala (semen-promoting), and stanya (galactagogue, milk-promoting) actions (JAIMS critical review, 2025).
Its traditional applications are distinctive. The powdered tuber taken with cow's milk is the classic galactagogue preparation, used to support milk production after childbirth; combined with long pepper (pippali) powder it was used as an anabolic preparation for malnutrition in children. Taken with honey it was used for excessive menstruation; and fresh tuber juice with cumin seeds and sugar was used for spermatorrhoea (Frontiers in Pharmacology review). Its classical formulations include Vidaryadi ghrita, and it appears in Satavaryadi ghrita, Sarasvatarishta, and Ashwagandharishta (same review). Formulations are traditionally used across conditions including wasting (kshaya), consumption (rajayakshma), cough (kasa), impotence (klaibya), bleeding disorders (raktapitta), and gouty disorders (vatarakta) (IJAAR classical review). These are traditional claims, not clinical proof: the human evidence is assessed separately below.
What modern research says
Blood pressure — see our Vidarikand article
To avoid duplicating evidence: a randomized human trial of this plant (blood pressure) is covered in our Vidarikand article: a 12-week, single-blind, placebo-controlled study in 30 stage-1 hypertensives, where 3 g of tuber powder daily lowered systolic pressure by 25 mmHg versus placebo. Small and single-blind: a lead, not a fact.
Lactation (small clinical study)
The one human study touching vidari's traditional galactagogue use is described in a 2019 review of lactogenic plants: 30 patients were divided into two groups, one receiving P. tuberosa and the other the standard Ayurvedic comparator shatavari churna for deficient lactation, with outcomes including the baby's weight (Journal of Pharmacognosy and Phytochemistry review). The published detail is thin and the design is unclear: this is at most a preliminary signal, not proof that vidari increases breast milk. A separate preclinical study found puerarin raised prolactin and milk yield in a rat model: rats, not women (Bioinformation).
Everything else is preclinical
A 2021 peer-reviewed review catalogues animal and laboratory findings, antidiabetic effects in diabetic rats, anti-stress effects in rats (reduced corticosterone), antioxidant activity, but these are rat studies, and the review itself concludes that mechanisms of action are unproven and that toxicity and clinical studies "shall be the focus of future investigations" (Frontiers in Pharmacology review). Do not read human efficacy into them.
What the evidence does not support (yet)
Rejuvenation, aphrodisiac or fertility effects, galactagogue effects, and anti-diabetic effects in humans: none of these traditional claims has been tested in a published, adequate human trial.
Dosage
No human dose of vidari has been established for any of its traditional uses. The human regimen from the blood-pressure trial covered in our Vidarikand article, 3 g of tuber powder per day in two divided doses for 12 weeks, was a research dose for hypertension, not a dose for lactation, fertility, or general rejuvenation. Classical forms such as tuber powder taken with milk carry no verified dosing in the sources reviewed. Do not self-dose based on traditional use.
Safety & contraindications
In that 12-week blood-pressure trial, the tuber was well tolerated with no reported adverse effects: but that is 15 people over 12 weeks, which proves little about long-term safety (Vidarikand article). No longer-term human safety data were found in the sources reviewed. Animal toxicology adds caution at high doses: repeated dosing of the tuber water extract in rats caused 100% mortality by day 21 at 2,000 mg/kg/day, attributed to liver toxicity (Bharti et al., 2021): far above the trial's 3 g/day, but another reason not to self-experiment with unstudied doses. The tuber contains isoflavonoids including puerarin, genistein, and daidzein; the review notes estrogenic-pathway activity only in animal studies, not a human hormonal claim, and there are no adequate safety data for pregnancy or breastfeeding. Note that its traditional galactagogue use is exactly that: traditional, not clinically tested. Anyone on blood-pressure medication should only consider it with a clinician's involvement, given the blood-pressure-lowering signal in the one trial.
FAQs
Is vidari the same as vidarikand?
Yes: both names refer to the tuber of Pueraria tuberosa. On this site, our Vidarikand article covers the clinical trial evidence (blood pressure) and safety, while this Vidari article covers the classical Ayurvedic entry: properties, traditional uses, and formulations.
What is vidari used for in Ayurveda?
It is a classical rasayana (rejuvenative) tonic, traditionally used for strength, vitality, reproductive health, and lactation support: with sweet taste and cooling potency in Ayurvedic terms (JAIMS critical review, 2025). Traditional use is not clinical proof.
Does vidari increase breast milk?
Traditionally, tuber powder taken with cow's milk is the classic galactagogue preparation (Frontiers in Pharmacology review). The human data is one small, poorly detailed study comparing it with shatavari (phytojournal review): not proof. Nursing mothers should not self-experiment; involve a clinician.
Does vidari help male fertility?
Classical texts credit it with vrishya (aphrodisiac) and shukrala (semen-promoting) actions, and animal studies report spermatogenic effects (Frontiers in Pharmacology review). The sources reviewed include no human trial of this.
How much vidari is used?
No dose is established for its traditional uses. The only human regimen, 3 g of tuber powder per day for 12 weeks, comes from the blood-pressure trial in our Vidarikand article and does not transfer to lactation or fertility uses.
Is vidari safe while breastfeeding?
There are no clinical safety data for breastfeeding, despite the traditional galactagogue use. Its isoflavonoids have shown estrogenic-pathway activity only in animal studies: not a human hormonal claim. Do not use while nursing without a clinician's guidance.
Sources
- Bharti R et al. "Pueraria tuberosa: A Review on Traditional Uses, Pharmacology, and Phytochemistry." Frontiers in Pharmacology. 2021;11:582506 — PMC · PMC7941752 (traditional uses, formulations, preclinical pharmacology; repeated-dose rat mortality at 2,000 mg/kg/day attributed to hepatotoxicity; calls for toxicity and clinical studies)
- Kushwaha AK et al. "Critical Review on Vidarikanda (Pueraria tuberosa Dc.)." Journal of Ayurveda and Integrated Medical Sciences. 2025;10(6):128–135 — jaims.in (Ayurvedic properties: madhura rasa, shita virya, guru-snigdha guna; classical indications)
- "Vidarikanda (Pueraria tuberose Linn.): A Review from Bruhatrayi and Nighantu." International Journal of Applied Ayurved Research — ijaar.in (classical properties and formulations across Samhitas and nighantus)
- "Lactogenic activity of medicinal plants" review (includes the 30-patient P. tuberosa vs shatavari lactation study). Journal of Pharmacognosy and Phytochemistry. 2019;8(5):2479–2482 — phytojournal.com
- The single randomized human trial (blood pressure) is covered in our Vidarikand article — Swastik
Related herbs
Disclaimer
This article is for educational purposes only and is not medical advice. Herbal products can interact with medications and are not suitable for everyone. Talk to a qualified healthcare practitioner before use — especially if you are pregnant, breastfeeding, managing a medical condition, or taking prescription medicines.